Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab Plus Nivolumab With Chemotherapy in First-Line Advanced NSCLC
NCT04623775Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 19
01
Overview
Phase 2, randomised trial of relatlimab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Treatment-Related Adverse Events Leading to Discontinuation at 12 weeks and Objective Response Rate at 14.8 months. Started Feb 2021; status: completed.
02
Drugs
relatlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04623775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623775.